Amoryn supplement claims review
This article was originally published in The Tan Sheet
Executive SummaryBioneurix provides a reasonable basis for general performance claims for its Amoryn dietary supplement in treating mild to moderate depression, however, evidence presented by the marketer does not support claims that the product's main ingredient, hyperforin, has been clinically proven to treat "severe" depression, according to the Electronic Retailing Self-Regulation Program. The Council of Better Business Bureaus program commenced the review of online claims as part of its ongoing monitoring efforts. Costa Mesa, Calif.-based Bioneurix said it would take the recommendations into consideration for future ads and has already taken steps to change some wording on its Web site
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.